KYMR (Kymera Therapeutics, Inc.) Earnings per share for the last four quarters

Public company logo of Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics (KYMR) relies on the development of protein degradation methods and is currently in the clinical testing phase with no current sales. The YoY ttm net income per share growth visualizes profit dynamics, where -0.70 captures the current value of the indicator. Prospects are driven by colossal demand for targeted oncology and strict adherence to green chemistry principles in the creation of new drugs.

KYMR kymeratx.com Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

Kymera Therapeutics, Inc. - analytical breakdowns and key metrics (KYMR)

- business market valuation indicators:
Fundamental valuation:Kymera (KYMR)
Signature product of Kymera

This indicator measures the annual change in net income per share over the last 12 months, allowing investors to filter out short-term fluctuations and assess the real business momentum via the EPS TTM YoY metric. The current value of -0.70 reflects the financial performance of Kymera Therapeutics (KYMR) during the implementation of its AI platform for creating innovative targeted protein degradation drugs.

Competitor analysis for Kymera Therapeutics

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|IDYA (IDEAYA Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX